Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang
1. Zydus Lifesciences to acquire Agenus' biologics manufacturing facilities for $75 million. 2. Agenus will streamline focus on colorectal cancer drug development post-acquisition. 3. Analysts predict bot/BAL approval by 2028-2029, with significant market potential. 4. Agenus aims to reduce cash burn below $50 million in 2025; cash balance at $18.5 million. 5. Agenus stock rose 17% to $5.86 following recent developments.